Browse > Home / Pharmacy Industry News / Lakewood-Amedex Inc. To Develop Broad Spectrum Influenza Drug To Include H1N1 And H5N1 Type A Strains

Lakewood-Amedex Inc. To Develop Broad Spectrum Influenza Drug To Include H1N1 And H5N1 Type A Strains

August 28, 2009

Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical visitor developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad image anti-influenza product into clinical studies.

Lakewood-Amedex’s nRNA product works by selectively silencing targeted genes in the viral genome. The company is building on the before successful animal model study at what place mice infected with H1N1 type A influenza virus were given two doses of the L-A nRNA product and all survived while have the direction of and placebo dosed mice entirely died not more than six days. In joining L-A previously published a study demonstrating the effectiveness of its technology against the lethal H5N1 “bird flu” influenza virus in which a simple intra-nasal dose of the company’sitting nRNA consequence protected 100% of the infected chickens while placebo treated chickens all died within seven days.

Steve Parkinson, L-A’sitting President and Chief Executive Officer, commented, “We had intended to develop our broadly to be applied influ-RNA product to treat seasonal flu and being of the class who any emergency stockpile product in the event of a further affray of avian influenza, but debt to the escalating global H1N1 pandemic and now the report of this virus having been isolated from turkeys in Chile, we feel it is dubious to have a product that can mark multiple strains of influenza and is useable year after year.”

Mr. Parkinson explained that the L-A yield does not work like a vaccine that stimulates the human host immune theory to produce antibodies targeted at the specific viral constrain composing the vaccine. Instead the nRNA product contains several inadequate oligonucleotide sequences that are mirror images to singular sites on the viral mRNA from the viral replicative genes. When the nRNA comes into contact through its specific target, it hybridizes with the viral mRNA locking this mRNA up and preventing produce of vital viral replicative proteins. Deprived of these, the virus is unable to make more itself and rendered unable to distribute and infect other cells.

Paul DiTullio, chief scientist concerning Lakewood-Amedex said, “We are essentially shutting the virus down in the infected body. By targeting the highly conserved replicative genes we have a product that should be useable for years even if the virus mutates. We are also hitting divers genetic sites and the chances of them all mutating in the same season is minimal. Even if the H1N1 strain does endure recombination through the deadly H5N1 strain our product will calm shut it down.” DiTullio added, “That is the limitation with vaccines. They stir up antibody production in the host against the surface antigens of the virus but unfortunately it is the surface antigens that mutate most of the time requiring a new vaccine to have being developed. Our product works independently of surface antigen mutation.”

Mr. Parkinson commented, “The Company intends to complete its pre-clinical facts package and inscribe human clinical trials as quickly as possible. We are talking to government agencies and potential partners and hope in a short time to have a universal anti-influenza product as an other to seasonal vaccines.”

About Lakewood-Amedex Inc.

Lakewood-Amedex is a privately held development-stage biopharmaceutical association with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications case its proprietary NuBiotics group of genera of anti-microbial products, proven to be efficient against a wide consort of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and others, and patents covering certain proprietary products targeting pandemic viral infections including Epstein Barr Virus (EBV), human and avian influenza, Hepatitis B and C and other clinical indications. The Company anticipates initiating full of common human feeling clinical trials for consisting of topics use of its Nu-3 NuBiotics compound in the near subsequent time for indications including diabetic ulcers and other topical infections. Future studies will involve the use of Nu-2 to treat broad spectrum antibiotic-resistant bacterial pulmonic and systemic infections. The troop is currently conducting a human IRB clinical have existence eager to improve treatment of nasopharyngeal carcinoma in Changsha, China. Lakewood-Amedex is headquartered in Sarasota, FL.

Source: Lakewood-Amedex Inc.

Written by Samanta · Filed Under Pharmacy Industry News